Coherus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 74   

Articles published

CHRS 21.95 -0.20 (-0.90%)
price chart
Coherus BioSciences and Baxter Announce Amendment to Etanercept ...
REDWOOD CITY, Calif. and DEERFIELD, Ill., April 15, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) and Baxter International Inc. (NYSE:BAX) today announced that they have amended certain financial terms of their collaboration ...
Trader's Recap: Coherus Biosciences, Inc. (NASDAQ:CHRS), The Habit ...
Coherus Biosciences, Inc. (NASDAQ:CHRS) belongs to Healthcare sector. Its weekly performance is 0.43%. On last trading day company shares ended up $23.62.
Coherus Biosciences' Lock-Up Period To Expire Tomorrow (NASDAQ:CHRS)  sleekmoney
Coherus BioSciences to Report First Quarter 2015 Financial Results on May 11  Satellite PR News (press release)
Coherus Biosciences (CHRS) Jumps: Stock Moves Up 12.7%
Coherus Biosciences, Inc. (CHRS - Snapshot Report) was a big mover last session, as the company saw its shares rise almost 13% on the day.
JUNO Therapeutics Inc (JUNO); Coherus Biosciences Inc (CHRS), Stemline ...
Juno Therapeutics Inc (NASDAQ:JUNO) is up by 15% as of Thursday afternoon, following the release of its first-ever earnings report since its IPO.
Baxter International Inc. (BAX) Amends Partnership Contract With Coherus ...
Baxter International Inc. (NYSE:BAX) and Coherus BioSciences Inc (NASDAQ:CHRS) announced financial changes to their 2013 partnership contract regarding the development and marketing of CHS-0214, a biosimilar to Amgen, Inc.'s (NASDAQ:AMGN) ...
Baxter Amends Financial Provisions of Coherus Collaboration  Brazil Business Today (subscription)
Update: Short Interest of Coherus BioSciences, Inc. Increases by 13.9%
The short interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) has increased from 656,898 on March 13,2015 to 748,301 on March 31,2015 .
Biotech Stocks with Pessimistic Trend - Coherus Biosciences (CHRS), Cytori ...  Wall Street Observer
Mid-Day Changers: Coherus Biosciences, Inc. (CHRS), Miller Energy Resources ...  WallStreet Scope
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock
REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share, before ...
IPO Report: Coherus BioSciences (CHRS)  Equities.com
Related articles »  
Another skin biotech: Coherus BioSciences files for a $86 million IPO
Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
Biosimilar drug developer Coherus jumps into IPO pool  Silicon Valley Business Journal (blog)
Coherus Files for IPO: Biotech to Biosimilars  24/7 Wall St.
Related articles »  
Coherus Biosciences (CHRS) Jumps: Stock Adds 7.7% in Session
Coherus Biosciences, Inc. (CHRS - Snapshot Report) was a big mover last session, as the company saw its shares rise roughly 8% on the day.
Coherus BioSciences to Report Fourth Quarter and Year End 2014 Financial ...
REDWOOD CITY, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call ...